Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
| Price | $3.73 |
|---|---|
| Market cap | $20.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 3.19-21.4 |
| Beta | 0.75 |
Explore NEUP's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.